Dr. Karen Smith Joins Sucampo’s Board of Directors
July 18 2017 - 4:05PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global
biopharmaceutical company, today announced that Karen Smith, M.D.,
Ph.D., M.B.A., LLM., has joined the Company’s Board of Directors on
July 15. Dr. Smith is Executive Vice President, R&D, and
Chief Medical Officer at Jazz Pharmaceuticals.
“I am excited to welcome Karen to Sucampo’s Board of Directors,”
said Peter Greenleaf, Chairman and Chief Executive Officer of
Sucampo. “As a proven leader and innovation strategist with
significant clinical and product development expertise, Karen will
be an indispensable part of our continued growth and evolution as
we advance our late-stage pipeline in highly specialized areas of
significant unmet medical need.”
Dr. Smith brings to Sucampo over 25 years of senior leadership
and executive experience with both major pharmaceutical companies
and start-up biotechnology organizations. Her product development
expertise spans various therapeutic areas and includes over 20
major drug and device approvals in North and Latin America, Asia,
Europe and Australia. From 2011 to 2015, she was Senior Vice
President of Global Medical Affairs and Global Therapeutic Area
Head for Allergan, a multi-specialty health care company. From 2007
to 2010, Dr. Smith served initially as AstraZeneca’s Vice President
of External Medical Relations, and later Vice President of Global
Development. She held an array of management and medical roles at
the Bristol-Myers Squibb Company in Australia, Canada and the
United States. In 2001, she was also the Chief Executive Officer of
Boron Molecular, a specialist fine chemicals manufacturing company.
Dr. Smith previously served on the Women’s Advisory Board for
Ironman Corporation, Susan G. Komen and Girl Scouts; and is
currently Advisor to the CEO of Forward Pharma.
Dr. Smith holds a B.A.Sc. and a B.Sc. from the Curtin
University, an M.D. from the University of Warwick (UK), a Ph.D. in
oncology molecular genetics from the University of Western
Australia, an M.B.A. from the University of New England (Australia)
and a L.L.M. in medical law from the University of Salford
(UK).
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of highly
specialized medicines. Sucampo has a late-stage pipeline of
product candidates in clinical development for orphan disease
areas, including VTS-270, a 2-hydroxypropyl-beta-cyclodextrin
product with a specific compositional fingerprint that has been
granted orphan designation in the U.S. and Europe and is in a
pivotal Phase 2b/3 clinical trial for the treatment of Niemann-Pick
Disease Type C-1, a rare progressive genetic disorder.
VTS-270 also has been granted breakthrough therapy designation in
the U.S. Sucampo has an exclusive option for the North
American rights to CPP1-x/sulindac, which is in Phase 3 development
for the treatment of familial adenomatous polyposis and has been
granted orphan drug designation in the U.S. The company has two
marketed products – AMITIZA and RESCULA. For more information,
please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation,
AMITIZA and RESCULA are registered trademarks of Sucampo and its
affiliates.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals). Twitter LinkedIn
Contact
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Sep 2023 to Sep 2024